Although immune checkpoint inhibitors (ICIs) have yet to demonstrate their benefit in patients with osteosarcoma (NCT02406781), blockade of PD-1 and PD-L1 interactions showed their potential to improve anti-tumor response in preclinical studies [18]. This evidence concerns the gene CD274 and neoplasm.